Do you need to stop a GLP-1 before trying to get pregnant with PCOS?

Dr. Linda's take

If you have PCOS and you are taking one of these medications, there is a question underneath the question you came here with. It is not only whether you should stop before trying to conceive. It is whether your body might get there before you have decided anything at all. PCOS is the population where this matters most, because the same medication that is helping your metabolic picture can also bring back a cycle that has been unreliable for years. Women with PCOS are often told for a long time that pregnancy will be hard, and then a treatment shifts something and the old assumption quietly stops being true. That is not a warning. For many women it is welcome news. But it does mean the timing conversation should happen early, not after a surprise. What follows is what the drug labels and the PCOS research actually say, so you can walk into your clinician's office already knowing which questions are yours to ask. This is general education, not a plan for your body.

Why can fertility come back unexpectedly on a GLP-1 when you have PCOS?

Start with the baseline. In PCOS, absence of ovulation is one of the core features, and it leads to irregular menstrual periods or no periods at all. PCOS is the most common cause of anovulatory infertility, meaning infertility that results from the absence of ovulation. That is the situation many women with PCOS have organized their expectations around, sometimes for a decade.

This medication class can change that baseline. In a six-month study of women with PCOS and a body mass index above 25, 83% of patients presented with oligomenorrhea and anovulatory cycles before treatment, and after treatment with semaglutide, ovulatory cycles were observed in 52.5% of previously anovulatory women. In a broader review of this medication class in PCOS, GLP-1 receptor agonist use was associated with improved metabolic parameters, menstrual regularity, and increased rates of natural pregnancy.

Read those two findings together and you can see the shape of the problem. Ovulation can resume without any obvious announcement, in a body that has been treating irregular cycles as normal, in someone who may not be tracking anything because there has been nothing reliable to track. For a deeper look at how this medication class is being studied in PCOS generally, see our overview of semaglutide and PCOS.

What do the FDA labels say about stopping before a planned pregnancy?

This is where the labels are unusually direct, and it is worth quoting them closely rather than paraphrasing loosely.

The FDA prescribing information for Wegovy states that because of the potential for fetal harm, patients should discontinue Wegovy at least 2 months before they plan to become pregnant, to account for the long half-life of semaglutide. The Ozempic label carries the same instruction in its own words, saying to discontinue Ozempic in women at least 2 months before a planned pregnancy due to the long washout period for semaglutide.

The reasoning behind that interval is pharmacology, not caution for its own sake. Semaglutide leaves the body slowly, so stopping the week before you start trying would not clear the drug in any meaningful sense. The two-month figure exists because the labels are accounting for that long tail. Notice also what the instruction assumes: that the pregnancy is planned, and that there is a date to count backward from. That assumption is exactly what does not hold for a woman whose ovulation has just been restored by the drug itself.

What do the labels say about use during pregnancy?

The Wegovy label states that weight loss offers no benefit to a pregnant patient and may cause fetal harm, and it directs that Wegovy be discontinued in pregnant patients who are using it for weight reduction. The label also notes that based on animal reproduction studies, there may be potential risks to the fetus from exposure to semaglutide during pregnancy, and that available pharmacovigilance data and data from clinical trials with Wegovy use in pregnant patients are insufficient to establish a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. The Ozempic label states that there are limited data with semaglutide use in pregnant women to inform a drug-associated risk for adverse developmental outcomes, and that Ozempic should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

That phrase, insufficient to establish, is doing honest work. It does not say the drug is proven harmful in human pregnancy. It says the human evidence is not there, while the animal evidence raises enough concern that the labels do not wait for certainty. There is also a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Wegovy during pregnancy, which is how that missing human data slowly gets built.

In the PCOS research literature, the same logic shows up as a general principle: it is recommended to avoid pregnancy as long as anti-obesity medications are being taken.

How does this change the conversation for PCOS specifically?

For most people taking one of these medications, the label instruction about stopping two months before a planned pregnancy is a straightforward scheduling matter. For PCOS it is not, and the reason is worth naming plainly.

If a medication is simultaneously the thing you would need to stop before pregnancy and the thing that made pregnancy newly possible, then the plan cannot be built after the fact. The window in which a person with PCOS discovers her fertility has returned may be the same window in which she is still taking the drug. That is not an argument against the medication. It is an argument for having the contraception and timing conversation at the start of treatment rather than somewhere down the line, and for a clinician who knows your reproductive plans to be the one holding that thread. None of this is something an article can decide for you, and side effects are a separate part of the same discussion, covered in our guide to side effects when you have PCOS.

What should you ask your clinician?

If you want a structured way to open that conversation, Body Good Studio's quiz maps your symptoms to a starting point before you talk with a clinician.

Frequently asked questions

Do the FDA labels say to stop a GLP-1 before trying to get pregnant?

For semaglutide, yes. The Wegovy prescribing information says to discontinue Wegovy at least 2 months before a planned pregnancy because of the long half-life of semaglutide, and the Ozempic label gives the same two-month instruction, citing the long washout period. What that means for your situation is a question for the clinician who prescribed it.

Can a GLP-1 actually restore ovulation if you have PCOS?

The research suggests it can for some women. In a six-month study of women with PCOS and a body mass index above 25, ovulatory cycles were observed in 52.5% of previously anovulatory women after treatment with semaglutide. A broader review of this medication class in PCOS reported improved menstrual regularity and increased rates of natural pregnancy.

Why two months, and not two weeks?

Because of how long the drug stays in the body. The Wegovy label ties the two-month interval to the long half-life of semaglutide, and the Ozempic label ties it to the long washout period. The interval reflects clearance, not a symbolic waiting period.

What do the labels say if pregnancy happens while you are still taking it?

The Wegovy label states that weight loss offers no benefit to a pregnant patient and may cause fetal harm, and directs that Wegovy be discontinued in pregnant patients who are using it for weight reduction. This is a conversation to have with a clinician immediately rather than something to work out alone.

Is the risk to a pregnancy proven?

Not in humans, and the labels are explicit about that gap. The Wegovy label says available pharmacovigilance data and data from clinical trials with Wegovy use in pregnant patients are insufficient to establish a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes, while noting that animal reproduction studies suggest there may be potential risks to the fetus. Unknown is not the same as safe, which is why the labels take the position they take.

Does this article tell me whether to stop?

No. This is general education about what the labels and the research say, not medical advice, and it cannot account for your history, your reasons for treatment, or your timeline. That is a conversation for you and a licensed clinician.

References

1. National Institute of Child Health and Human Development (NICHD) (2026). What is Polycystic Ovary Syndrome (PCOS)? National Institutes of Health. https://www.nichd.nih.gov/health/topics/pcos/conditioninfo (Accessed 2026-07-16).
2. Carmina E, Longo RA (2026). Evidence That Semaglutide Represents an Important Tool for Treatment of Irregular Menses and Chronic Anovulation in Women with Polyendocrine Metabolic Ovarian Syndrome. Journal of Clinical Medicine, via PMC (National Library of Medicine). https://pmc.ncbi.nlm.nih.gov/articles/PMC13362893/ (Accessed 2026-07-16).
3. Machado MF, Shunk T, Hansen G, Harvey C, Fulford B, Hauf S, Schuh O, Kaldas M, Arcaroli E, Ortiz J, De Gaetano J (2024). Clinical Effects of Glucagon-Like Peptide-1 Agonist Use for Weight Loss in Women With Polycystic Ovary Syndrome: A Scoping Review. Cureus, via PMC (National Library of Medicine). https://pmc.ncbi.nlm.nih.gov/articles/PMC11389649/ (Accessed 2026-07-16).
4. Bednarz K, Kowalczyk K, Cwynar M, Czapla D, Czarkowski W, Kmita D, Nowak A, Madej P (2022). The Role of GLP-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome. International Journal of Molecular Sciences, via PMC (National Library of Medicine). https://pmc.ncbi.nlm.nih.gov/articles/PMC9029608/ (Accessed 2026-07-16).
5. U.S. Food and Drug Administration / Novo Nordisk (2026). WEGOVY (semaglutide) injection and tablets - Prescribing Information. DailyMed, National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b (Accessed 2026-07-16).
6. U.S. Food and Drug Administration / Novo Nordisk (2026). OZEMPIC (semaglutide) injection, for subcutaneous use - Prescribing Information. DailyMed, National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79 (Accessed 2026-07-16).